What Do Kansas Medical Records Reveal About Ozempic and Gastroparesis?
Latest update (2026-01)
FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]
From General Health Awareness to Specific Legal Concerns
If you or a loved one developed gastroparesis after taking Ozempic, you may be wondering how to connect the dots between the medication and your symptoms. Decades of pharmacovigilance research have established that drug-induced gastrointestinal side effects can be serious and require careful documentation. This page examines what Kansas medical records reveal about Ozempic and gastroparesis, helping you understand the clinical context and your next steps.
Understanding Ozempic and Its Gastrointestinal Risks
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for weight management. Among its known risks, gastrointestinal adverse reactions are prominent. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).
Gastroparesis: A Serious Gastrointestinal Condition
Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. The clinical presentation of gastroparesis overlaps with the gastrointestinal adverse effects reported with Ozempic, including dyspepsia (1.9% placebo, 3.5% Ozempic 0.5 mg, 2.7% Ozempic 1 mg), gastroesophageal reflux disease (0% placebo, 1.9% Ozempic 0.5 mg, 1.5% Ozempic 1 mg), and gastritis (0.8% placebo, 0.8% Ozempic 0.5 mg, 0.4% Ozempic 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate that Ozempic can induce or exacerbate symptoms consistent with gastroparesis. Mechanistically, GLP-1 receptor agonists like semaglutide slow gastric emptying as part of their pharmacodynamic effect. This delay in gastric motility is a known action that contributes to the therapeutic benefit of reducing postprandial glucose excursions. However, in susceptible individuals, this effect may become pathological, leading to clinically significant gastroparesis. The reported gastrointestinal adverse reactions, including dyspepsia and gastroesophageal reflux disease, are consistent with impaired gastric emptying. The frequency of these events, particularly during dose escalation, suggests a dose-dependent relationship between semaglutide exposure and gastrointestinal motility disturbances.
Legal Implications and Lawsuit Settlement Criteria
The adequacy of warnings regarding Ozempic and gastroparesis is a critical risk consideration. The prescribing information for Ozempic does not explicitly list gastroparesis as a warning or precaution. Instead, it describes gastrointestinal adverse reactions as common and notes that serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The label advises caution in patients with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, there is no specific warning about the risk of developing gastroparesis, which may leave patients and healthcare providers unaware of this potential serious adverse effect. This gap in labeling could be relevant in legal contexts, as patients who develop gastroparesis after using Ozempic may argue that the manufacturer failed to provide adequate warnings. For affected patients, attorney-related considerations include the need to establish a causal link between Ozempic use and the development of gastroparesis. Key factors in such cases include the timeline between exposure to Ozempic and the onset of symptoms, the absence of other causes of gastroparesis (e.g., diabetes-related autonomic neuropathy, prior surgery, or idiopathic causes), and the severity of the condition. The reported gastrointestinal adverse reactions, including those leading to discontinuation, provide a basis for arguing that Ozempic can cause significant gastrointestinal harm. The timeline is particularly important: the majority of nausea, vomiting, and diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), suggesting that symptoms may emerge early in treatment. However, gastroparesis may develop more insidiously, and patients may not immediately associate their symptoms with the medication.
Summary of Evidence and Next Steps
In summary, the evidence indicates that Ozempic is associated with gastrointestinal adverse reactions that overlap with the clinical presentation of gastroparesis. The mechanistic link through delayed gastric emptying is plausible, and the reported frequencies of dyspepsia, gastroesophageal reflux disease, and other symptoms support this association. The lack of explicit warnings about gastroparesis in the prescribing information raises questions about the adequacy of risk communication. Patients who develop gastroparesis after using Ozempic should consult with a healthcare provider and consider legal counsel to evaluate their individual circumstances, including the timing of symptoms and any other contributing factors. References https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the link between Ozempic and gastroparesis?
Ozempic (semaglutide) slows gastric emptying as part of its mechanism, which can lead to symptoms consistent with gastroparesis such as nausea, vomiting, and bloating. Clinical trials show higher rates of gastrointestinal adverse reactions in Ozempic users compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).
What are the criteria for an Ozempic gastroparesis lawsuit?
Key criteria include documented Ozempic use, a confirmed gastroparesis diagnosis, a temporal relationship between exposure and symptom onset, and exclusion of other causes. The lack of explicit warnings about gastroparesis in the prescribing information may support claims of inadequate risk communication.
How can an attorney help with an Ozempic gastroparesis claim?
An attorney can evaluate the strength of your case, gather medical evidence, establish causation, and navigate legal proceedings. They can also assess whether the manufacturer failed to provide adequate warnings, which is central to many product liability claims.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Community Resource & Benefit Desk
Request archival records or inquire about member-exclusive transition and benefit programs.